FSR PFDD Agenda Draft

Externally-Led Patient Focused Drug Development Meeting on Sarcoidosis
November 6, 2024
10:00am – 3:00pm ET
Virtual

Welcome (5 min)
Mary McGowan, FSR CEO

Opening Remarks (5 min)
Dr. Sally Seymour (Pending Acceptance of Invitation)

Clinical Overview and Background on the condition (10 min)
Dr. Lisa Maier, FSR Scientific Advisory Board Member

Overview of Discussion Format (10 min)
TBD

Topic 1: Symptoms and Impacts on Daily Living-Panel (30 min)
To include live polling questions and a panel discussion. Panel to be comprised of 3 very diverse speakers. While recognizing there's a population well-managed by steroids, the panel will be focused on the severe form of sarcoidosis because these are the constituents FSR serves. Panelists will specifically address their unmet needs and the quality of life impacts of the condition.

Large-Group Facilitated Discussion on Topic 1 (60 min)
Patients and care partners in the audience are invited to add to the dialogue.

Break (5 minutes)

Reconvene Meeting (2 minutes)
Host

Topic 2: Current Approaches to Treatment-Panel (30 min)
Topic 2 will also be comprised of polling questions and a panel discussion. A panel of 4-5 patients and/or caregivers will provide comments on current approaches to treatment and preferences for future developments.
Large-Group Facilitated Discussion on Topic 2 (65 min)
   Patients or care partners in the audience are invited to add to the dialogue.

Summary and Closing Remarks (5 min)
   Moderator